Telecom could become one of Nifty’s biggest sectors after financials, says ICICI Securities

Piramal Pharma is gaining attention as a key investment theme following a bullish outlook on India's telecom sector. ICICI Securities believes that a potential 16-20% rise in telecom tariffs will boost 5G monetisation and improve cash flows. This macro shift is expected to drive significant growth in the broader market, with the brokerage highlighting the company's expanding Contract Development and Manufacturing Organisation (CDMO) business as a major driver of its future value.
For investors, the stock represents an opportunity to benefit from a favourable macro environment and the company's strategic expansion in the global pharmaceutical manufacturing space. The focus now shifts to Piramal Pharma's ability to execute its growth plans and how it capitalises on the improving industry sentiment. Market participants will closely watch quarterly results and the progress of its CDMO initiatives to gauge the sustainability of this momentum.
Excerpt from CNBC-TV18
Published On Oct 28, 2026 | 13:20 IST Last Updated On Oct 28, 2026 | 13:20 IST Pankaj Pandey, Head of Retail Research at ICICI Securities, expects another 16-20% telecom tariff hike to improve 5G monetisation and cash flows, while limited competition could support long-term growth. The brokerage also highlighted…Read the original at CNBC-TV18
Affected stocks
Bullish2 stocksBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Piramal Pharma (PPLPHARMA).
- Category: Economy.
- AI reads the tone as positive (potentially bullish) for the stock.
- Assessed as a significant, market-relevant update.
- Also mentions RADICO.
Why it matters
A meaningful update for Piramal Pharma worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

















